CHARLES SCHWAB INVESTMENT MANAGEMENT INC - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 160 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.79 and the average weighting 0.1%.

Quarter-by-quarter ownership
CHARLES SCHWAB INVESTMENT MANAGEMENT INC ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$346,938
-36.3%
258,909
-14.9%
0.00%
Q2 2023$544,774
-37.1%
304,343
+36.7%
0.00%
Q1 2023$866,346
+23.2%
222,711
+7.7%
0.00%
Q4 2022$703,225
-35.8%
206,831
+3.2%
0.00%
Q3 2022$1,095,000
+21.4%
200,501
+0.3%
0.00%
Q2 2022$902,000
-37.0%
199,977
+3.0%
0.00%
Q1 2022$1,432,000
+18.3%
194,197
+3.2%
0.00%
Q4 2021$1,210,000
+10.4%
188,1490.0%0.00%
Q3 2021$1,096,000
-77.2%
188,149
-59.5%
0.00%
-100.0%
Q2 2021$4,800,000
+0.9%
465,058
+2.8%
0.00%0.0%
Q1 2021$4,758,000
-34.2%
452,244
-3.2%
0.00%
-33.3%
Q4 2020$7,231,000
-4.0%
467,069
-9.5%
0.00%0.0%
Q3 2020$7,533,000
-10.4%
515,909
+16.3%
0.00%
-25.0%
Q2 2020$8,405,000
+13.3%
443,721
+14.9%
0.00%0.0%
Q1 2020$7,418,000
+10.4%
386,138
+10.2%
0.00%0.0%
Q4 2019$6,717,000
+103.0%
350,365
+1.9%
0.00%
+100.0%
Q3 2019$3,309,000
+81.5%
343,961
+13.0%
0.00%
+100.0%
Q2 2019$1,823,000
+22.8%
304,258
+19.8%
0.00%0.0%
Q1 2019$1,484,000
-41.1%
254,031
-5.5%
0.00%
-50.0%
Q4 2018$2,520,000
-45.6%
268,847
-1.2%
0.00%
-33.3%
Q3 2018$4,632,000
+5.9%
271,988
+5.7%
0.00%0.0%
Q2 2018$4,374,000
+93.7%
257,410
+53.0%
0.00%
+50.0%
Q1 2018$2,258,000
+56.5%
168,188
+11.9%
0.00%
+100.0%
Q4 2017$1,443,000
-6.4%
150,289
+7.1%
0.00%0.0%
Q3 2017$1,542,000
+46.7%
140,360
+21.0%
0.00%0.0%
Q2 2017$1,051,000
-5.4%
116,036
+34.1%
0.00%0.0%
Q1 2017$1,111,000
+42.8%
86,514
+4.5%
0.00%0.0%
Q4 2016$778,000
+26.1%
82,752
+30.6%
0.00%0.0%
Q3 2016$617,000
+52.0%
63,364
+4.7%
0.00%0.0%
Q2 2016$406,000
-23.7%
60,498
+1.5%
0.00%0.0%
Q1 2016$532,000
-31.4%
59,616
+1.8%
0.00%0.0%
Q4 2015$776,000
+28.7%
58,545
+2.4%
0.00%0.0%
Q3 2015$603,000
-63.6%
57,180
-6.1%
0.00%
-50.0%
Q2 2015$1,657,000
+10.1%
60,868
+23.9%
0.00%0.0%
Q1 2015$1,505,000
+29.7%
49,145
+58.6%
0.00%0.0%
Q4 2014$1,160,000
+8.2%
30,980
+1.1%
0.00%0.0%
Q3 2014$1,072,000
-3.9%
30,657
+27.9%
0.00%0.0%
Q2 2014$1,116,000
+110.2%
23,973
+39.5%
0.00%
+100.0%
Q1 2014$531,000
+37.9%
17,185
+2.5%
0.00%0.0%
Q4 2013$385,00016,7650.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q3 2020
NameSharesValueWeighting ↓
AIGH Capital Management LLC 1,773,474$2,376,4561.12%
AlphaCentric Advisors LLC 1,125,000$1,507,5000.86%
Tejara Capital Ltd 1,077,388$1,443,7000.82%
Palo Alto Investors LP 5,675,876$7,605,6740.72%
Birchview Capital, LP 571,832$766,2550.65%
Altium Capital Management LP 740,000$991,6000.52%
Avidity Partners Management LP 8,298,570$11,120,0840.45%
Worth Venture Partners, LLC 445,981$597,6150.36%
SILVERARC CAPITAL MANAGEMENT, LLC 561,955$753,0200.23%
DAFNA Capital Management LLC 192,678$258,1890.08%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders